Key information about Dymista® Control
Key information about Dymista® Control
Click through the table below to learn more about the contraindications, warnings and interactions in relation to Dymista® Control.
Those with a hypersensitivity to azelastine hydrochloride, fluticasone propionate or any of the excipients listed in the patient information leaflet, should NOT use Dymista® Control.1
In the following instances, customers should be referred to their doctor for assessment before using Dymista® Control:1
Pregnant, suspected pregnancy or planning to have a baby
Breastfeeding
Severe liver disease, due to an increased risk of suffering from side effects that affect the whole body
Tuberculosis or any type of untreated infection
Fever or infection in the nasal passages or sinuses
Recent injury or surgery to the nose or mouth or problems with ulceration in the nose
A history of increased ocular pressure, glaucoma and/or cataracts
Those transferring from a systemic corticosteroid
Those who have been using intranasal corticosteroids at high doses and/or for prolonged periods (3 months or more).
They may be at greater risk of systemic effects and may require medical intervention before continuing with intranasal corticosteroids. Potential systemic effects may include:Cushing’s syndrome, Cushingoid features, adrenal suppression
Cataract, glaucoma
More rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression
Customers experiencing any of these systemic effects must be referred to their doctor.Changes in vision (e.g. blurred vision or other visual disturbances) after using systemic or topical corticosteroids.
Customers taking sedatives/central nervous system (CNS) medicines (e.g. opioids, barbiturates, benzodiazepines, anxiolytics, sleep medications, hypnotics) should be warned of the potential increase in their sedative effect when used alongside Dymista® Control.1
Customers taking the following medicines should be referred to their doctor before using Dymista® Control:1
Concomitant use of other corticosteroid products, such as tablets, creams, ointments, asthma medications or similar intranasal sprays or eye/nose drops
Medicines for HIV (ritonavir or cobicistat)
Ketoconazole.
Always consult the BNF or SmPC for potential interactions with the customer’s other medication.
Advice and special considerations
Dose1
Recommended dosage: for adults, one spray into each nostril, twice a day (morning and evening)
Maximum daily dose: two sprays into each nostril
Dymista® Control should be used regularly for full therapeutic benefit
Remember that your customer may have combined their previous corticosteroid nasal spray with an OTC oral antihistamine. Because Dymista® Control combines an intranasal corticosteroid and intranasal antihistamine, your customer should discontinue their previous hay fever medication.
Duration1
-
Please note – Your customer needs to assess their symptoms within 7 days of starting Dymista® Control. If their symptoms are not well controlled, they may not have hay fever:
If Dymista® Control does NOT lead to an improvement in symptoms within 7 days, your customer should stop treatment or seek advice from their doctor
If, within 7 days, symptoms have improved but are NOT adequately controlled, they should also seek advice from their doctor or pharmacist
Dymista® Control should not be used for more than 3 months continuously without consulting a doctor.
How to use10,11
It is important that Dymista® Control is administered correctly. You can find full details on how to use Dymista® Control in the Pharmacy Essential Guide.
CLEAR
Blow your nose to clear nostrils.
Shake the bottle gently.
INSERT
Close 1 nostril with a finger. Place spray pump tip just into your other nostril.
Tilt head forward slightly. Do NOT tilt head back. Open mouth. Do NOT spray directly onto the nasal septum (the wall between your 2 nostrils).
SPRAY AND BREATHE
Keeping bottle upright and mouth open, pump once gently. As you spray, breathe in lightly through the treated nostril.
Repeat in the other nostril. Wipe off tip with clean tissue. Replace dust cap.
SHAKE
Before you prime the bottle, shake it gently.
Remove the clear plastic dust cap from the spray pump tip of the bottle.
PRIME
Hold bottle upright with 2 fingers on the shoulders of the spray pump and your thumb on the bottom of bottle.
Press upward with your thumb and release. Repeat pumping action. Once you see a fine mist, your Dymista® Control nasal spray is ready to use.
CLEAR
Blow your nose to clear nostrils.
Shake the bottle gently.
INSERT
Close 1 nostril with a finger. Place spray pump tip just into your other nostril.
Tilt head forward slightly. Do NOT tilt head back. Open mouth. Do NOT spray directly onto the nasal septum (the wall between your 2 nostrils).
SPRAY AND BREATHE
Keeping bottle upright and mouth open, pump once gently. As you spray, breathe in lightly through the treated nostril.
Repeat in the other nostril. Wipe off tip with clean tissue. Replace dust cap.
SHAKE
Before you prime the bottle, shake it gently.
Remove the clear plastic dust cap from the spray pump tip of the bottle.
PRIME
Hold bottle upright with 2 fingers on the shoulders of the spray pump and your thumb on the bottom of bottle.
Press upward with your thumb and release. Repeat pumping action. Once you see a fine mist, your Dymista® Control nasal spray is ready to use.
CLEAR
Blow your nose to clear nostrils.
Shake the bottle gently.
You may wish to refer your customer to the Patient Information Leaflet that also includes full instructions on how to use Dymista® Control:
Highlight the sections on how to prepare and prime the spray
Remind them to spray the suspension once into each nostril keeping the head tilted forward
Advise them on how to clean the spray once a week and how to unblock the pump (without using a sharp object as this can damage the spray pump and affect the dose of medicine administered)
Side effects
Full details about possible side effects can be found in the SmPC
Very common: epistaxis (nosebleeds)1
Common: headache, dysgeusia (unpleasant taste), unpleasant smell1
The unpleasant taste is often related to incorrect method of application. Remind customers to tilt their head forward when administering the spray1 (as shown in 'how to use')
Dymista® Control has minor influence on the ability to drive and use machines1
Benzalkonium chloride in Dymista® Control may cause oedema of the nasal mucosa when used long term.1
When to seek medical advice11
A severe allergic reaction (very rare) may occur, indicated by swelling of face, lips, tongue or throat which may cause difficulty in swallowing/breathing and a sudden onset of skin rash. If this happens, your customer should call 999
Customers should contact their doctor if they experience blurred vision or other visual disturbances
Customers should inform their doctor or pharmacist if they experience discomfort due to irritation or swelling inside the nose, which may be caused by benzalkonium chloride, an excipient in Dymista® Control
Customers should seek advice from their doctor if Dymista® Control does NOT lead to an improvement in symptoms within 7 days
Customers should seek advice from their doctor or pharmacist if symptoms have improved within 7 days, but are NOT adequately controlled
Customer should seek advice from their doctor if they have used Dymista® Control continuously for 3 months
When to refer
Refer customers to a doctor when the following symptoms are presented:10
Persistent moderate to severe symptoms that are not relieved by Dymista® Control after 7 days, and/or continue to have a significant effect on quality of life
Customers who have used Dymista® Control continuously for 3 months
-
Symptoms that may be associated with an alternative diagnosis (see following section), including:
Fever that is not improving or worsening
Persistent cough
Coloured nasal discharge
Unilateral symptoms
Blood-stained nasal discharge
Recurrent nose bleeds
Nasal pain
Loss of sense of smell
Visual disturbances
Customers who have attempted to use an intranasal spray without success due to an obstruction or structural abnormality in the nose.
UK-DTC-2025-00003 March 2025